Werewolf Therapeutics Inc (HOWL) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Werewolf Therapeutics Inc stock $0.85, price $0.99, that is 14.0% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Werewolf Therapeutics Inc
HOWL · USExpensive (fair value 14% below the price) and weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $0.3080 – $18.83 · fair‑value band $0.6392 – $1.07 · the $0.9908 price screens above the $0.8523 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Werewolf Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions.
Show moreShow less
The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma.
The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer.
In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Stock analysis
Werewolf Therapeutics Inc (HOWL) currently trades at $0.9908, while our estimate is $0.8523, 14% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.6392 (bear) to $1.07 (bull), the price of $0.9908 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Werewolf Therapeutics Inc reported revenue of $0 in FY2025 versus $4.1M in FY2021. Reported net income was −$60.8M in FY2025.
Key figures
Market cap $48.2M Micro · P/S ratio 2.27 · EPS (TTM) $−0.7300 · Return on equity −120% · Return on assets (EBIT) −46.3% (5-year average) · Operating margin −122% · Revenue (TTM) $21.0M · Free cash flow −$60.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 222% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −14%, HOWL screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director sold shares worth $456,119 and none bought.
- SaleLuke EvninDirector27× since Nov 17, 2025: 3,552,501 shares, avg. $0.6415$2.3MJul 7, 202610b5-1 plan
- SaleRA CAPITAL MANAGEMENT, L.P.10% owner3× since May 8, 2026: 1,430,914 shares, avg. $0.4964$710,365Jun 17, 2026
- SalePeter Kolchinsky10% owner678,226 shares at $0.3739$253,569Jun 11, 2026
- SaleMPM BioImpact LLCFormer 10% Owner199,732 shares at $0.9176$183,275Dec 4, 202510b5-1 plan
- SaleMPM BioVentures 2014 (B), L.P.Former 10% Owner199,732 shares at $0.9176$183,275Dec 4, 202510b5-1 plan
- SaleUBS Oncology Impact Fund L.P.10% owner141,927 shares at $0.9643$136,855Dec 1, 202510b5-1 plan
- SaleMPM Asset Management Investors BV2014 LLC10% owner141,927 shares at $0.9643$136,855Dec 1, 202510b5-1 plan
- SaleMPM Oncology Innovations Fund GP LLC10% owner3× since Nov 17, 2025: 412,830 shares, avg. $0.9245$381,672Nov 25, 202510b5-1 plan
- SaleMPM BioVentures 2014 GP LLC10% owner195,666 shares at $0.9176$179,551Nov 25, 202510b5-1 plan
- SaleMPM BioVentures 2014 LLC10% owner2× since Nov 17, 2025: 217,164 shares, avg. $0.9307$202,121Nov 20, 202510b5-1 plan
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Werewolf Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs HOWL |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs HOWL |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs HOWL |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs HOWL |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs HOWL |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs HOWL |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs HOWL |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs HOWL |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs HOWL |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs HOWL |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Werewolf Therapeutics Inc (HOWL) overvalued or undervalued?
What is the fair value of HOWL?
What is the quality score of HOWL?
What is the price target for Werewolf Therapeutics Inc (HOWL)?
What is the Werewolf Therapeutics Inc stock forecast for 2026?
What is the revenue of Werewolf Therapeutics Inc (HOWL)?
What is the intrinsic value of Werewolf Therapeutics Inc (HOWL)?
Is Werewolf Therapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of HOWL?
How much is Werewolf Therapeutics Inc worth?
What do the bullish and bearish scenarios say about HOWL?
How solid is the balance sheet of Werewolf Therapeutics Inc (HOWL)?
How far is HOWL from its 52-week high?
Which stocks are comparable to Werewolf Therapeutics Inc?
Is Werewolf Therapeutics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Werewolf Therapeutics Inc (HOWL)?
What should I pay attention to with Werewolf Therapeutics Inc right now?
Key figures of Werewolf Therapeutics Inc
How large is the market capitalisation of Werewolf Therapeutics Inc (HOWL)?
What is the P/S ratio of Werewolf Therapeutics Inc (HOWL)?
What are the earnings per share of Werewolf Therapeutics Inc (HOWL)?
What is the return on equity of Werewolf Therapeutics Inc (HOWL)?
What is the EBIT return on assets of Werewolf Therapeutics Inc (HOWL)?
What is the operating margin of Werewolf Therapeutics Inc (HOWL)?
How much free cash flow does Werewolf Therapeutics Inc (HOWL) generate?
How much net cash does Werewolf Therapeutics Inc (HOWL) hold?
Watch Werewolf Therapeutics Inc in the live analysis
One click puts Werewolf Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.